Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)

7.540 +0.020 (+0.27%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nuvectis Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)
With clinical catalysts on the horizon and a seasoned biotech insider doubling down, Could Nuvectis Pharma (NASDAQ:NVCT)* Become the Next Summit Therapeutics (NASDAQ: SMMT)? 
Via News Direct
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma's NXP900: Could This Revolutionary Cancer "Inactivator" Transform Oncology Treatment?
Truffle Pigs Blog Highlights Potential Game-Changing Cancer Therapy with Unique Mechanism of Action 
Via News Direct
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
From Market News Alerts
Via Business Wire
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
Research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) 
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
From Market News Alerts
Via Business Wire
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
From Nuvectis Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
From Nuvectis Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing. 
Via Benzinga
S&P 500 Moves Lower; US Crude Oil Inventories Increase
Via Benzinga
Topics Stocks
Dow Falls Over 100 Points; US Producer Prices Rise In October
Via Benzinga
Topics Stocks
US Stocks Edge Lower; Cisco Earnings Top Views
Via Benzinga
Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort
Via AB Newswire
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
From Nuvectis Pharma, Inc.
Via GlobeNewswire
From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update
The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B). 
Via News Direct
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
From PESG Research
Via Business Wire
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
From Nuvectis Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge. 
Via News Direct
Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment
Report spotlights Nuvectis Pharma's (NASDAQ: NVCT) NXP900 as a potential game-changer in NSCLC treatment, noting its unique mechanism targeting SRC/YES1 kinases and promising preclinical data 
Via News Direct
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
From PESG Research
Via Business Wire
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS